Complete Program Guide can be downloaded here

See below for Agenda, Speakers, and Sponsors for the 2025 event

2025 Agenda

Program Guide can be downloaded here

Topics Include:

Basic & Translational Science of Psychedelics | Clinical Models: Ketamine, Psilocybin, and Ibogaine | Global Practices & Comparative Frameworks | Legal & Policy Pathways for Regulation | Therapeutic Facilitation & Patient Journeys | Coverage Models & Health System Integration | Industry & Manufacturing Perspectives | Economics of Psychedelic Therapies | Patient Perspectives & Family Narratives | Future Directions: Implementation, Barriers, & Spirituality

Speakers

Keynote Speaker

W. Bryan Hubbard

CEO, Americans for Ibogaine

Complete roadmap for ibogaine implementation in Texas


Psilocybin, Ibogaine, and Ketamine: the Basic and Translational Science

Michael Thase, MD

Professor of Psychiatry,
Perelman School of Medicine

How Ketamine/Esketamine Opened the Doors to Psychedelics Research

Paul Regier, PhD

Research Assistant Professor of
Psychiatry, Perelman School of Medicine

Penn’s Clinical Trial of Psilocybin for OUD

Dalibor Sames, PhD

Professor of Chemistry and The Zuckerman Mind Brain Behavior Institute, Columbia University

Mechanisms of Ibogaine and Multidimensional Therapeutic Potential

Anna Rose Childress, PhD

Adjunct Professor of Psychiatry, Perelman School of Medicine

Long Day's Journey into Psilocybin Research: Local and Regional Barriers (Virtual)


Therapeutic and Clinical Perspectives

Gail Serruya, MD

Voyage Healing

Clinical Delivery of Spravato and Ketamine in Real Practice


Therapeutic and Clinical Applications

Kim Adams


Writer & Speaker on Addiction & Grief;
Founder of LYT Marketing

Moderator

Carlos Alvear Lopez, MD

Medical Director, Inscape Recovery

Current Modes of Ibogaine Practice in Mexico (Virtual)

Patrick Fishley, RN BScN CCRN
& Michele Fishley, LPN

Iboga Practitioners, Soul Reflections Int'l

Road Maps and Barriers to adding Ibogaine to the US Model (Virtual)

Bruno Rasmussen Chaves, MD

Physician; Veracruz do Brasil

Ibogaine’s Clinical Success in Brazil, and Legal Roadblocks Beyond Drug Scheduling (Virtual)

Maurice Hinson, MD

Hospitalist, Jamaica Hospital Medical Center; Founder and Executive Director, MediRootz Medical Group

Clinical Perspectives in the Implementation of Ibogaine-assisted Therapy

Martin Polanco, MD

Founder, The Mission Within treatment center

5-MeO-DMT Treatment Applications (Virtual)


Psilocybin-Assisted Therapy Educational Play

Neal Usatin

Editor of Netflix’s How to Change Your Mind;
CEO, Psychedelic Oncology;
Founder, NJ for Fungi and Plant Medicines

Denise Rue, LCSW

Therapist, New Jersey Psychedelic
Therapy Association

Jason Konner, MD

Physician; Psychedelic Oncology; Memorial Sloan Kettering Cancer Center


Gaetano Lardieri

Founder, Quantum WellCare

Moderator

Public and Private Coverage Models

Sherry Rais

Enthea; California Institute of Integral Studies; Psychedelic Research Group

Nichelle Santos

Founder, CannaCoverage of Trenton, NJ

Rekha Philip

Chief of Staff, Journey Clinical

Courtney Gable, LPC

Independent KAT Clinician


Legal Considerations

Robert Rush, Esq.

Attorney, Law Office of Robert T. Rush;
Rights and Reason Project

DEA vs. Psychedelic Science: The Fight to Save DOI

Ken Wolski, RN, MPA

Executive Director, Coalition for
Medical Marijuana-NJ;
Chairman, Trenton Cannabis Advisory Committee

Panelist: Current Legal Frameworks

Brett Phelps

Attorney, Owner, Phelps Law Office;
Students for Sensible Drug Policy


Panelist (Virtual): Panelist: Current Legal Frameworks

Graham Moore

Educational Outreach Director,
Mass Healing

Victory from the Jaws of Defeat -
Hard Lessons from a Failed Ballot Measure Campaign

Matt Brockmier

Entheogyn PBC, Antithesis Law

Panelist: Current Legal Frameworks

Hamilton Morris

Chemist, Journalist

Panelist: Current Legal Frameworks


Patient Experiences

Jenny Rhubright

End-of-Life Doula;
Certified Dementia Care Specialist

Mike Holovacs

Veteran, United States Air Force
(2001-2007)

Michael D. Brennan

Coalition for Medical Marijuana-NJ, Inc.;
Americans for Safe Access

Andrew J. Walker

Advocate for cannabis and alternative plant therapies for Veterans, first responders, and law enforcement

Jared Rinehart

Heroic Hearts Project

Evelyn Shoop, PMHNP-BC

Board-Certified Psychiatric-Mental Health Nurse Practitioner

Joseph McKay

Clusterbusters / FDNY (ret.)


Pharmaceutical Perspectives

Rhonda DeSantis

Facilitator, cultivater, manufacturer;
CEO & Founder, Psylutions

Building Natural Psilocybin Medicine for Real Patient Journeys


 Sapan Patel

PharmD.

Economics of Ketamine/Esketamine

Victor Acero, PhD

Post-Doc, CPDRE at OSU

Current Ibogaine Use Survey

Taweh Hunter

Research Assistant, CPDRE

Current Ibogaine Use Survey

Mattha Busby

Journalist

Bad Shamans: The Dark Side of Psychedelics

Tribute to Norma Lotsof


The Penn Psychedelics Collaborative honors Norma Lotsof, whose lifelong dedication helped bring ibogaine from the margins of underground discovery into the modern dialogue on addiction treatment and psychedelic medicine. Together with her late husband, Howard Lotsof, Norma’s advocacy, compassion, and perseverance laid the foundation for much of the ibogaine research and practice that exists today. Norma now faces significant medical and financial challenges, and the global ibogaine community has come together to support her through this GoFundMe campaign. We invite our community to join in honoring her extraordinary contributions and helping ensure she receives the care and dignity she deserves.  

Tribute to Nolan R. Williams, MD


The Penn Psychedelics Collaborative honors Nolan R. Williams, MD, was a pioneering psychiatrist and neuroscientist whose work transformed how we think about treating severe mood disorders, particularly through his leadership in ibogaine research. As Director of the Stanford Brain Stimulation Lab, he helped design and study carefully monitored ibogaine protocols for veterans and others living with depression, PTSD, traumatic brain injury, and substance use disorders, documenting rapid, sustained reductions in mood and trauma symptoms after a single treatment. By pairing ibogaine with sophisticated brain imaging and electrophysiology, he began to map how this powerful medicine reshapes neural circuits involved in mood, opening new paths toward safer, more precise therapies. Nolan’s work offered hope to people who had exhausted conventional options, and his blend of scientific rigor, clinical courage, and deep compassion continues to guide the emerging field of ibogaine assisted care for mood and trauma related disorders.  

Special thanks to our sponsors